Zork said:
Que tal amigos, para lo que no saben el finasteride es una droga qeu anula la conversion de testosterona en dht, por lo que es usada para la caida del cabello en dosis bajas y en dosis mas altas para tratar inflamaciones prostáticas y no se que mas...enm fin, para los que tengan algo de material o experiencia: ¿interfiere de algun modo en los ciclos de estroides este compuesto?, ¿quita eficacia a agun anabolico o los deribados de la dht como estanozolol, oximetolona, etc.?
Espero qeu alguien me pueda ayudar, muchas gracias
Arriba!!!
Como estas zork....
El fina solo funciona con la testosterona y la boldenona efectivamente.
Con la nandrolona o trembolona es contraproducente usarlo, ya ke estas se convierten a DHN , una forma mas suave para los foliculos pilosos... y si vos blokias la conversión de estas... fuiste... por ke la nandrolona y la trembolona si van a llegar a los receptores del pelo (ke deberían ocuparse por la DHN en este caso) y al ser mas fuertes incluso ke la DHT... adios con tu pelito si tenes tendencia alopécica.
Con los derivados de la DHT , NO ES EFICAZ , en lo absoluto.... es imposible blokiar la acción de estos esteres por ke de por si ya son DHT....
Y NO QUITA EFICACIA, al contrario de lo ke la mayoría creen.... la DHT producida en el cuerpo por la convercion del uso exogeno (o T endogeno) de testosterona parece no necesitarse a nivel muscular, ya que ella no nesesita transformarse para generar hipertrofia muscular (por ke en este no hay 5 alfa reductasa para ejerser su efecto como DHT)
Acá te dejo un estudio para ke leas un poco:
J Clin Endocrinol Metab. 2004 Nov 30; [Epub ahead of print] Related Articles, Links
Exogenous Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T.
Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.
Departments of Medicine, Emory University School of Medicine (J.L.T.) and Biostatistics (F.D.B.), Rollins School of Public Health, Atlanta, Georgia, and Department of Medicine (S.T.P., J.K.A., B.D.A., A.M.M., W.J.B.), Veterans Affairs Puget Sound Health Care System (B.D.A. and A.M.M.), and Geriatric Research, Education and Clinical Center (A.M.M.), University of Washington School of Medicine, Seattle, WA.
Testosterone (T) therapy in older men with low serum testosterone (T) levels increases lean body mass (LBM) and decreases fat mass (FM). These changes might improve physical performance and strength; however, it has not been established whether T therapy improves functional outcome in older men. Moreover, concerns exist about the impact of T therapy on the prostate in older men. The administration of finasteride, which partially blocks the conversion of T to the more potent androgen, dihydrotestosterone (DHT), attenuates the impact of T replacement on prostate size and PSA. We hypothesized that T replacement in older hypogonadal men would improve physical function and that the addition of finasteride to this regimen would continue to provide the T-induced improvements in physical performance, strength, and body composition. Seventy men with low serum T (<350ng/dl), age 65 and older, were randomly assigned to receive one of three regimens for 36 months: T enanthate 200 mg intramuscularly every two weeks with placebo pills daily (T-only), T enanthate 200 mg every two weeks with 5 mg finasteride daily (T+F), or placebo injections and pills (placebo). We obtained serial measurements of timed physical performance, grip strength, lower extremity strength, body composition (by DEXA), fasting cholesterol profiles and hormones. Fifty men completed the 36-month protocol. After 36 months, T therapy significantly improved performance in a timed functional test when compared with baseline and placebo (4.3 +/- 1.6% [mean +/- SEM, T-only] and 3.8 +/- 1.0% [T+F] vs. -5.6 +/- 1.9% for placebo, [P < 0.002 for both T and T+F vs. placebo]), and increased handgrip strength compared with baseline and placebo [P < 0.05]. T therapy increased LBM (3.77 +/- 0.55 kg [T-only] and 3.64 +/- 0.56 kg [T+F] vs. -0.21 +/- 0.55 kg for placebo, [P < 0.0001]), decreased FM, and significantly decreased total cholesterol, low-density lipoprotein (LDL-C), and leptin, without affecting high-density lipoprotein (HDL), adiponectin or fasting insulin levels. These results demonstrate that T therapy in older men with low serum T improves physical performance and strength over 36 months both when administered alone or when combined with finasteride and suggest that high serum levels of DHT are not essential for these beneficial effect of T in men.
PMID: 15572415 [PubMed - as supplied by publisher]
Aca tenes otro estudio en ratas al cual llegan a la misma conclusion:
Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E222-E227. Epub 2004 Sep 14. Related Articles, Links
Inhibition of 5{alpha}-reductase blocks prostate effects of testosterone without blocking anabolic effects.
Borst SE, Lee JH, Conover CF.
VA Medical Center, GRECC-182, 1601 SW Archer Rd., Gainesville, FL 32608-1197.
[email protected]).
We studied the effect of the 5alpha-reductase inhibitor MK-434 on responses to testosterone (T) in orchiectomized (ORX) male Brown Norway (BN) rats aged 13 mo. At 4 wk after ORX or sham surgery, a second surgery was performed to implant pellets delivering 1 mg T/day or placebo pellets. During the second 4 wk of the study, rats received injections of MK-434 (0.75 mg/day) or vehicle injections. Treatment with T elevated serum T to 75% above that for sham animals (P = 0.002) and did not affect serum dihydrotestosterone (DHT) or serum estradiol. T treatment also caused an elevation of prostate T and a marked elevation of prostate DHT. During the second half of the study, ORX rats lost an average of 18.86 +/- 4.62 g body wt. T completely prevented weight loss, and the effect was not inhibited by MK-434 (P < 0.001). ORX produced a nonsignificant trend toward a small (5%) decrease in the mass of the gastrocnemius muscle (P = 0.0819). This trend was also reversed by T, and the effect of T was not blocked by MK-434. T caused a significant 16% decrease in subcutaneous fat that was not blocked by MK-434 (P < 0.05). Finally, T caused a 65% decrease in urine excretion of deoxypyridinoline, a marker of bone resorption, and again the effect was not blocked by MK-434 (P < 0.0001). In contrast, T caused a greater than fivefold increase in prostate mass, and the effect was almost completely blocked by MK-434 (P < 0.0001). This study demonstrates that 5alpha-reductase inhibitors may block the undesirable effects of T on the prostate, without blocking the desirable anabolic effects of T on muscle, bone, and fat.
PMID: 15367394 [PubMed - as supplied by publisher]
Saludos!
Please Scroll Down to See Forums Below 
.